Figure 1.
EFS, PFS, and time to progression. Kaplan-Meier estimates of (A) EFS, (B) PFS, and (C) time to progression by investigator assessment among the 101 patients with LBCL treated with axi-cel in cohorts 1 and 2 of phase 2.
EFS, PFS, and time to progression. Kaplan-Meier estimates of (A) EFS, (B) PFS, and (C) time to progression by investigator assessment among the 101 patients with LBCL treated with axi-cel in cohorts 1 and 2 of phase 2.
